SynDevRx, Inc
- Biotech or pharma, therapeutic R&D
SynDevRx is in Phase 1b/2 studies leading the field of metabo-oncology – the intersection of cancer and obesity/diabetes. Our asset evexomostat is the first drug with potent effects on cancer, obesity and diabetes – an estimated market >$40B
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}